Skip to main content
. 2025 Feb 8;27(8):3535–3542. doi: 10.1007/s12094-025-03852-x

Table 3.

Comparison of incidence rates between the group with immunotherapy with pembrolizumab versus the group without immunotherapy

“IO positive group” “IO negative group”
p = 0.038
Hazard Ratio 0.116 95.0% CI (0.015–0.883)
Incidence Rate 6.3 per 1000-patients at risk 62.2 per 1000-patients at risk

CI = Confidence Interval; IO = Immunotherapy